For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their ...
President Donald Trump is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut the costs associated with prescription drugs.
Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and potential side effects.
The GLP-1 PR has been a little too good. Everyone knows the drugs lead to rapid weight loss — including participants in ...
Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...
President Donald Trump and nine major pharmaceutical companies today announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his ...
(Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own deals in an attempt to avoid potentially ...
Incyte (INCY) looks undervalued vs the 2028 Jakafi patent cliff; see why non-Jakafi growth and pipeline optionality could ...
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Anna Chorniy, Icahn School of Medicine at Mount Sinai; Institute for Humane Studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results